前收市價 | 0.8618 |
開市 | 0.8410 |
買盤 | 0.8410 x 800 |
賣出價 | 0.9078 x 1100 |
今日波幅 | 0.8410 - 0.8650 |
52 週波幅 | 0.8220 - 14.4800 |
成交量 | |
平均成交量 | 266,946 |
市值 | 31.261M |
Beta 值 (5 年,每月) | 0.21 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -2.5700 |
業績公佈日 | 2023年11月08日 - 2023年11月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 4.55 |
Rain Therapeutics Inc. (NASDAQ:RAIN) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Greetings and welcome to the Rain Oncology Fourth Quarter and Full Year 2022 Earnings Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry of Live Site Advisors. Thank you. You may […]
Rain Therapeutics Inc (NASDAQ: RAIN) announced preliminary data from Phase 2 basket trial evaluating milademetan for MDM2-amplified advanced solid tumors. "Treatment with milademetan led to tumor regression in patients previously treated with a multitude of therapies across a range of cancers. We look forward to expanding this dataset as the trial continues to enroll," said Avanish Vellanki, co-founder & CEO. Seventeen patients have been enrolled, 15 of whom have been dosed with milademetan. Ten